menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Raltegravir Therapy for Multi-Drug Resistant HIV

Program Information
Recommended
Raltegravir Therapy for Multi-Drug Resistant HIV
RestartResume
In the quest to find therapies for multi-drug resistant HIV, researchers have zeroed in on raltegravir. The latest data indicates this potent agent...
  • Overview

    In the quest to find therapies for multi-drug resistant HIV, researchers have zeroed in on raltegravir. The latest data indicates this potent agent provides the highest reported virologic suppression rate among multi-drug resistant patients. Is raltegravir proving more effective than antiretrovirals? Does it carry any prominent side effects? Dr. Roy Steigbigel, professor of medicine and pathology, molecular genetics and microbiology, and pharmacological sciences, and founding director of the Comprehensive AIDS Center at the State University of New York at Stony Brook, details his New England Journal of Medicine research on raltegravir therapy for multi-drug resistant HIV with host Dr. Mark Nolan Hill.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 9/19/19

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.